AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8045722 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 21
Study 8045722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 21
Study 2648791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (group 1)
Number of subjects: 36
Study 2648791 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 36
Study 28965137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 200
Study 28965137 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 200
Study 27620550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS) administration at a dose of 2 ng/kg
Number of subjects: 21
Study 27620550 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administration
Number of subjects: 21
Study 25268019 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of group behavioral activation (BA)
Number of subjects: 96
Study 25268019 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 96
Study 23406610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track preventive intervention
Number of subjects: 891
Study 23406610 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 891
Study 21735655 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol hydrochloride with behavioral modification
Number of subjects: 72
Study 21735655 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy only
Number of subjects: 72
Study 21735655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 19631790 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD) inserted into 20 women in Group 1 over the first 3 days of menstrual bleeding.
Number of subjects: 40
Study 19631790 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) followed without any intervention.
Number of subjects: 40
Study 16675080 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (five 30‐s static stretches)
Number of subjects: 0
Study 15184349 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 240
Study 15184349 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 240
Study 11207994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation therapy
Number of subjects: 68
Study 9037326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (Group 2)
Number of subjects: 57
Study 9037326 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive smokers (Group 3)
Number of subjects: 57
Study 9037326 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive nonsmokers with hypercholesterolemia (Group 4)
Number of subjects: 57
Study 9037326 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive smokers with hypercholesterolemia (Group 5)
Number of subjects: 57
Study 1742814 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC and 1.0 MAC)
Number of subjects: 30
Study 1742814 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.5 MAC and 1.0 MAC)
Number of subjects: 30
Study 1742814 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and Halothane
Number of subjects: 30
Study 6754064 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved fields
Number of subjects: 95
Study 6754064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantle
Number of subjects: 95
Study 6754064 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended fields
Number of subjects: 95
Study 6754064 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved fields followed by 6 cycles of MOPP
Number of subjects: 95
Study 6754064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantle (for upper torso presentations)
Number of subjects: 95
Study 6754064 — intervention group
Group type: COMPARATOR
Intervention: Involved fields alone (for upper torso presentations)
Number of subjects: 95
Study 31221169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scenarios describing seniors
Number of subjects: 586
Study 31221169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scenarios describing women
Number of subjects: 586
Study 28875447 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberation groups
Number of subjects: 444
Study 28875447 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 444
Study 26735540 — intervention group
Group type: EXPERIMENTAL
Intervention: Novum group (biomarker-assisted decision-making using MR-proADM levels)
Number of subjects: 398
Study 26735540 — intervention group
Group type: COMPARATOR
Intervention: Standard group (decision-making solely based on clinical assessment)
Number of subjects: 398
Study 26735540 — intervention group
Group type: EXPERIMENTAL
Intervention: Novum group
Number of subjects: 398
Study 26735540 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 398
Study 23607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-focusing strategy (10 minute instruction to cope with stress by posing two questions)
Number of subjects: 124
Study 23607331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 124
Study 23607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-focusing strategy
Number of subjects: 124
Study 23607331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 20146611 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded response condition
Number of subjects: 2
Study 20146611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspeeded response condition
Number of subjects: 2
Study 20146611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall memory accuracy
Number of subjects: 2
Study 19433387 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front zoledronic acid (ZA; 4 mg intravenously every 6 months)
Number of subjects: 301
Study 19433387 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months)
Number of subjects: 301
Study 19433387 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front zoledronic acid (ZA)
Number of subjects: 301
Study 19433387 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (ZA)
Number of subjects: 301
Study 16904446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (TER) 4 mg daily
Number of subjects: 745
Study 16904446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 14698800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg buprenorphine per day
Number of subjects: 513
Study 14698800 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg buprenorphine per day
Number of subjects: 513
Study 14698800 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg buprenorphine per day
Number of subjects: 513
Study 11331256 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave shock of 10 J in group A (first 45 patients)
Number of subjects: 80
Study 11331256 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave shock of 15 J in group B (last 35 patients)
Number of subjects: 80
Study 11331256 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductionless implantations overall
Number of subjects: 80
Study 11331256 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study at 3 months
Number of subjects: 80
Study 11331256 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate first shocks for rapid ventricular tachycardia or VF
Number of subjects: 80
Study 9850404 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine
Number of subjects: 100
Study 9850404 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 100
Study 7824150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nitroglycerin (5-20 micrograms/minute)
Number of subjects: 58
Study 7824150 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nitroglycerin (80-240 micrograms/minute)
Number of subjects: 58
Study 3415015 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with additional warming (humidified respiratory gases, warmed intravenous fluids, and a heating blanket over the legs; n = 5)
Number of subjects: 15
Study 3415015 — intervention group
Group type: COMPARATOR
Intervention: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with standard temperature management (no special warming measures; n = 10)
Number of subjects: 15
Study 31303367 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Radial Access (TRA)
Number of subjects: 205
Study 31303367 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 205
Study 30265636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rater training (7‐minute video incorporating frame‐of‐reference training elements)
Number of subjects: 47
Study 30265636 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 47
Study 27720659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-exercising device (MED)
Number of subjects: 282
Study 27720659 — intervention group
Group type: COMPARATOR
Intervention: No mouth-exercising device (Control)
Number of subjects: 282
Study 25768796 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilation (repeated plucking of lashes)
Number of subjects: 1300
Study 25768796 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1300
Study 23780477 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth initiated mentoring (YIM)
Number of subjects: 1173
Study 21091898 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g phenacetin (single oral dose)
Number of subjects: 70
Study 18208572 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg capsule of aprepitant
Number of subjects: 12
Study 18208572 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg capsule of aprepitant
Number of subjects: 12
Study 18208572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16772708 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 12,000 U twice/month for 6 months
Number of subjects: 20
Study 16772708 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonanemic CRF patients)
Number of subjects: 20
Study 14634405 — intervention group
Group type: COMPARATOR
Intervention: 5 cc saline
Number of subjects: 175
Study 14634405 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 cc 1% lidocaine (bilateral basal injection)
Number of subjects: 175
Study 14634405 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cc 1% lidocaine
Number of subjects: 175
Study 14634405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc 1% lidocaine
Number of subjects: 175
Study 14634405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc 1% lidocaine (bilateral basal plus apical injections)
Number of subjects: 175
Study 10952826 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 663
Study 10952826 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with elevated glucose levels
Number of subjects: 663
Study 10952826 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients in NYHA-FC III/IV
Number of subjects: 663
Study 10952826 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal glucose and insulin levels
Number of subjects: 663
Study 8770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 8770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 8770374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8448236 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation, guided imagery, and biofeedback training
Number of subjects: 13
Study 8448236 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 13
Study 3945762 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrol
Number of subjects: 49
Study 3945762 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 49
Study 31871717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education
Number of subjects: 0
Study 30522550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil, Jelfa tablets
Number of subjects: 15
Study 30522550 — intervention group
Group type: COMPARATOR
Intervention: Propycil tablets
Number of subjects: 15
Study 27671540 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Safety (HS) programme
Number of subjects: 49
Study 27671540 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Safety + Home Exercise (HS+HE) programme
Number of subjects: 49
Study 27671540 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care and social visits)
Number of subjects: 49
Study 27671540 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise (HE) programme
Number of subjects: 49
Study 23984944 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively arousing emotional events during navigation
Number of subjects: 0
Study 23984944 — intervention group
Group type: COMPARATOR
Intervention: Neutral or positively arousing emotional events during navigation
Number of subjects: 0
Study 23635626 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 300
Study 23635626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Metoclopramide 10 mg + Ondansetron 4 mg)
Number of subjects: 300
Study 23635626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 21115456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Number of subjects: 1378
Study 21115456 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam 1 g every 12 h for 5-14 days
Number of subjects: 1378
Study 21115456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 1378
Study 21115456 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam
Number of subjects: 1378
Study 18204830 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 582
Study 18204830 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 582
Study 16580114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulite F (N)
Number of subjects: 63
Study 16580114 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert (A)
Number of subjects: 63
Study 12728068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS) in the open arm
Number of subjects: 27
Study 12728068 — intervention group
Group type: COMPARATOR
Intervention: Standard 7-point BG profiles in the blinded arm
Number of subjects: 27
Study 12728068 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMS monitoring
Number of subjects: 27
Study 11255651 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD in diabetic nephropathy patients (group 1)
Number of subjects: 17
Study 11255651 — intervention group
Group type: COMPARATOR
Intervention: CAPD in non-diabetic patients (group 2)
Number of subjects: 17
Study 8973669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy (MVAC or MVEC)
Number of subjects: 166
Study 8973669 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy only
Number of subjects: 166
Study 8973669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (randomized group)
Number of subjects: 166
Study 8973669 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy only (randomized group)
Number of subjects: 166
Study 1434877 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 71
Study 1434877 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (medical treatment)
Number of subjects: 71
Study 6477250 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of 2% mepivacaine hydrochloride (with hyaluronidase added in 12 patients)
Number of subjects: 49
Study 6477250 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of hyaluronidase
Number of subjects: 49
Study 6477250 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 49
Study 30631986 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion chorion membrane (ACM)
Number of subjects: 22
Study 30631986 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM) putty
Number of subjects: 22
Study 30060688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian correspondence criteria
Number of subjects: 0
Study 30060688 — intervention group
Group type: COMPARATOR
Intervention: Randomized experiment
Number of subjects: 0
Study 27818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental home-based intervention package (improved solid-fuel stoves, kitchen sinks, solar disinfection of drinking water, hygiene promotion)
Number of subjects: 503
Study 27818376 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (early child stimulation programme)
Number of subjects: 503
Study 27818376 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental home-based intervention package
Number of subjects: 503
Study 24300901 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood drug involvement
Number of subjects: 359
Study 24300901 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood social cohesion
Number of subjects: 359
Study 24300901 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective neighborhood disorder
Number of subjects: 359
Study 22405251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin plus prednisolone (2 mg/kg per day for 15 days after C-reactive protein normalised)
Number of subjects: 248
Study 22405251 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day)
Number of subjects: 248
Study 21099590 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G
Number of subjects: 1565
Study 21099590 — intervention group
Group type: COMPARATOR
Intervention: Nonoxynol-9
Number of subjects: 1565
Study 18679597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (Jieze No.1 + Azithromycin)
Number of subjects: 393
Study 18679597 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieze No.1 alone
Number of subjects: 393
Study 18679597 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 393
Study 16291411 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg QD plus Metformin 500 mg TID (G + M)
Number of subjects: 99
Study 16291411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg QD plus Metformin 500 mg TID (R + M)
Number of subjects: 99
Study 11977438 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐Risk TLFB Interview
Number of subjects: 34
Study 11977438 — intervention group
Group type: COMPARATOR
Intervention: 27 sexual behavior frequency questions
Number of subjects: 34
Study 11977438 — intervention group
Group type: COMPARATOR
Intervention: Diet and nutrition using the TLFB format
Number of subjects: 34
Study 10424932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy using tissue plasminogen activator (tPA) at a dose of 0.9 mg/kg body weight.
Number of subjects: 100
Study 10424932 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase therapy.
Number of subjects: 100
Study 10424932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod therapy (STAT study).
Number of subjects: 100
Study 10424932 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (general).
Number of subjects: 100
Study 7480513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered tryptophan levels and ingestion of alcohol
Number of subjects: 0
Study 7480513 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic drinks
Number of subjects: 0
Study 2112180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (IV STK)
Number of subjects: 19
Study 2112180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen (IV TPA)
Number of subjects: 19
Study 1270971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (133.7 g)
Number of subjects: 0
Study 1270971 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (orange juice)
Number of subjects: 0
Study 1270971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (various doses)
Number of subjects: 0
Study 1270971 — intervention group
Group type: COMPARATOR
Intervention: Control experiments (weighing unsmoked tobacco and counting puffs)
Number of subjects: 0
Study 1270971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol days
Number of subjects: 0
Study 31919283 — intervention group
Group type: EXPERIMENTAL
Intervention: Project-based research ethics curriculum
Number of subjects: 0
Study 31919283 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31059697 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP (vasopressin)
Number of subjects: 0
Study 31059697 — intervention group
Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 0
Study 29173606 — intervention group
Group type: EXPERIMENTAL
Intervention: High ticagrelor loading dose (360 mg)
Number of subjects: 278
Study 29173606 — intervention group
Group type: COMPARATOR
Intervention: Conventional ticagrelor loading dose (180 mg)
Number of subjects: 278
Study 25801488 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 140
Study 25801488 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 140
Study 23818121 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-P4
Number of subjects: 21
Study 23818121 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-RV coil
Number of subjects: 21
Study 23818121 — intervention group
Group type: EXPERIMENTAL
Intervention: P4-RV coil
Number of subjects: 21
Study 23818121 — intervention group
Group type: EXPERIMENTAL
Intervention: P4-M2
Number of subjects: 21
Study 23818121 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous rhythm
Number of subjects: 21